Venom immunotherapy: worth the time and trouble

Clinical and Experimental Allergy

Volumn 39, Issue 6, 2009, Pages 774-776

  Heddle, R J ^a,b,e   Brown, S G A ^c,d  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e Division of Human Immunology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; INSECT VENOM; SNAKE VENOM;

ALLERGIC REACTION; ANAPHYLAXIS; EDITORIAL; HUMAN; IMMUNOTHERAPY; INSECT STING; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; QUESTIONNAIRE; RISK ASSESSMENT; SKIN TEST;

ALLERGENS; ANAPHYLAXIS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; INSECT BITES AND STINGS; QUALITY OF LIFE; WASP VENOMS;

EID: 66149136859     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2009.03271.x     Document Type: Editorial

References (18)

1. Hunt KJ, Valentine MD, Sobotka AK et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978 299 : 157 61.
2. Brown SGA, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003 361 : 1001 6.
3. Golden DBK. Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol 2005 115 : 439 47.
4. Bilo BM, Rueff E, Mosbech H et al. Diagnosis of Hymenoptera venom allergy. Allergy 2005 60 : 1339 49.
5. Van der Linden P-WG, Hack CE, Struyvenberg A, van der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and severity of anaphylaxis. J Allergy Clin Immunol 1994 94 : 151 9.
6. Brown SGA, Haas MA, Black JA et al. In vitro testing to diagnose venom allergy and monitor immunotherapy: a placebo-controlled crossover trial. Clin Exp Allergy 2004 34 : 792 800. (Pubitemid 38736796)
7. Pumphrey RSH. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000 30 : 1144 50.
8. Liew WK, Williamson E, Tang MLK. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol 2009 123 : 434 42.
9. Lockey RF, Turkeltaub PC, Olive ES et al. The Hymenoptera venom study. III. Safety of venom immunotherapy. J Allergy Clin Immunol 1990 86 : 775 80.
10. Mosbech H, Mueller U, EAACI. Side effects of insect venom immunotherapy: results from an EAACI multicenter study. Allergy 2000 55 : 1005 10.
11. Oude Elberink JNG, de Monchy JGR, van der Heide S et al. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002 110 : 174 82.
12. Oude Elberink JNG, van der Heide S, Guyatt GH, Dubois MD. Immunotherapy improves health related quality of life in adult patients with dermal reactions following yellow jacket stings. Clin Exp Allergy 2009 39 : 883 9.
13. Oude Elberink JNG, de Monchy JGR, Golden DBK et al. Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy. J Allergy Clin Immunol 2002 109 : 162 70.
14. Mueller U. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007 7 : 327 41.
15. Brown SGA, Franks RW, Baldo BA, Heddle RJ. Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania. J Allergy Clin Immunol 2003 111 : 187 92.
16. Brown SGA. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004 114 : 371 6.
17. Brown SGA, Blackman KE, Stenlake V, Heddle RJ. Insect sting anaphylaxis: prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J 2004 21 : 149 54.
18. Uguz A, Lack G, Pumphrey R et al. Allergic reactions in the community: a questionnaire survey of members of the anaphylaxis campaign. Clin Exp Allergy 2005 35 : 746 50.